S0777
Multiple Myeloma

A Randomized Phase III Trial of CC-5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341) Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
 

Our Locations

Penn Oncology Hematology Associates
Farm Journal Building
230 West Washington Square
Second Floor
Philadelphia, PA 19106
215-829-6088
Fax: 215-829-6104
www.pennoncology.com
Penn Oncology Hematology Associates at Radnor
250 King of Prussia Road
Suite 1B
Radnor, PA 19087
610-902-5950
Fax: 610-902-5959
Joan Karnell Cancer Center at Pennsylvania Hospital
Farm Journal Building
230 West Washington Square
First Floor
Philadelphia, PA 19106
215-829-6466
www.pennhealth.com/karnell

Working together with...